Tetravalent Rabies-Vectored Filovirus and Lassa Fever Vaccine Induces Long-term Immunity in Nonhuman Primates

Abstract

Background The objective of this study is to evaluate the immunogenicity of adjuvanted monovalent rabies virus (RABV)–based vaccine candidates against Ebola virus (FILORAB1), Sudan virus (FILORAB2), Marburg virus (FILORAB3), Lassa virus (LASSARAB1), and combined trivalent vaccine candidate (FILORAB1–3) and tetravalent vaccine candidate (FILORAB1–3 and LASSARAB) in nonhuman primates. Methods Twenty-four Macaca fascicularis were randomly assigned into 6 groups of 4 animals. Each group was vaccinated with either a single adjuvanted vaccine, the trivalent vaccine, or the tetravalent vaccine at days 0 and 28. We followed the humoral immune responses for 1 year by antigen-specific enzyme-linked immunosorbent assays and RABV neutralization assays. Results High titers of filovirus and/or Lassa virus glycoprotein-specific immunoglobulin G were induced in the vaccinated animals. There were no significant differences between immune responses in animals vaccinated with single vaccines vs trivalent or tetravalent vaccines. In addition, all vaccine groups elicited strong rabies neutralizing antibody titers. The antigen-specific immune responses were detectable for 1 year in all groups. Conclusions In summary, this study shows the longevity of the immune responses up to 365 days for a pentavalent vaccine—against Ebola virus, Sudan virus, Marburg virus, Lassa virus, and RABV—using a safe and effective vaccine platform.

Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity

“…There is evidence that it is the RABV-vector strategy that confers its long-term immune response to the foreign antigen. We have published on the longevity of the RABV-vector system in non-human primates with a tetravalent hemorrhagic fever vaccine 28 , and have additional supportive evidence in mice (unpublished).…”

A single-dose of the deactivated rabies virus vectored COVID-19 vaccine, CORAVAX, is highly efficacious and alleviates lung inflammation in the hamster model

“…Rapid fluorescent focus inhibition tests (RFFIT) were performed as previously described 12 . In brief, mouse neuroblastoma cells (NA) cultured in RPMI media (with 5 % FBS) were seeded in 96-well plates and incubated for 48 hours.…”

Utilization of Viral Vector Vaccines in Preparing for Future Pandemics

“…Another rhabdovirus, rabies virus (RABV), is also used as a vaccine vector and similarly can be pseudotyped with the GP of a different target virus, fully replacing the native RABV GP. While there are no RABV vector vaccine candidates in clinical development, the preclinical testing of inactivated vector vaccines for Ebola virus, Sudan virus, Marburg virus, and Lassa virus found the candidates to be immunogenic, either alone or when administered in combination as a multivalent vaccine [ 122 ].…”